Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2D | O15399 | 3/20 | 0.59 |
| ▸ | GRIN3B | O60391 | 3/20 | 0.59 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.59 |
| ▸ | GRIN2A | Q12879 | 3/20 | 0.59 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.59 |
| ▸ | GRIN2C | Q14957 | 3/20 | 0.59 |
| ▸ | GRIN3A | Q8TCU5 | 3/20 | 0.59 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.58 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.58 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | FAAH | O00519 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28246648 | 0.87 | MEN1 (0.52) | MEN1KMT2AFAAH | |
| SCHEMBL2636547 | 0.86 | MEN1 (0.68) | MEN1KMT2AFAAH | |
| SCHEMBL27779318 | 0.85 | MEN1 (0.51) | MEN1KMT2AFAAH | |
| SCHEMBL4959434 | 0.85 | ALDH1A1 (0.59) | MEN1KMT2AFAAH | |
| SCHEMBL27953755 | 0.85 | MEN1 (0.54) | MEN1KMT2AFAAH | |
| SCHEMBL2925616 | 0.85 | MEN1 (0.60) | MEN1KMT2A | |
| SCHEMBL5169485 | 0.85 | FAAH (0.63) | FAAH | |
| SCHEMBL5931753 | 0.85 | TACR3 (0.56) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL15718800 | 0.85 | MEN1 (0.51) | MEN1KMT2AFAAH | |
| SCHEMBL17748901 | 0.85 | CCR3 (0.53) | MEN1KMT2AFAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026102147-A1 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | Treeline Biosciences, Inc. (US) | 2026-05-15 | — | — | WO | disclosed |
| CN-103596960-B | 6, 7-dihydroimidazo [2,1-B ] [1,3] oxazine fungicides | 大塚制药株式会社 | 2016-11-16 | — | — | CN | disclosed |
| EP-2697232-B1 | 6,7-DIHYDROIMIDAZO[2,1-B][1,3]OXAZINE BACTERICIDES | OTSUKA PHARMA CO LTD (JP) | 2016-05-18 | — | — | EP | disclosed |
| WO-2015086693-A1 | PYRAZOLOPYRIMIDIN-2-YL DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2015-06-18 | — | — | WO | disclosed |
| US-9051333-B2 | 6,7-dihydroimidazo [2,1-b] [1,3]oxazine bactericides | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-06-09 | — | — | US | disclosed |
| EP-2697232-A1 | 6,7 - DIHYDROIMIDAZO [2, 1 - B][1, 3]OXAZINE BACTERICIDES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-02-19 | — | — | EP | disclosed |
| CN-103596960-A | 6, 7-dihydroimidazo [2,1-B ] [1,3] oxazine fungicides | OTSUKA PHARMA CO LTD | 2014-02-19 | — | — | CN | disclosed |
| US-20140031342-A1 | 6,7-DIHYDROIMIDAZO [2,1-b] [1,3]OXAZINE BACTERICIDES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-01-30 | — | — | US | disclosed |
| WO-2012141338-A1 | 6,7 - DIHYDROIMIDAZO [2, 1 - B] [1, 3] OXAZINE BACTERICIDES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-10-18 | — | — | WO | disclosed |
| US-20110263557-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2011-10-27 | — | — | US | disclosed |
| EP-2271619-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2011-01-12 | — | — | EP | disclosed |
| WO-2009126535-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2009-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140031342-A1 | 6,7-DIHYDROIMIDAZO [2,1-b] [1,3]OXAZINE BACTERICIDES | BRD1, OXA1L, QDPR | GRIN2D 615/4885GRIN3B 2634/4885GRIN1 1154/4885 |
| US-20110263557-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | GPR119, GPR55, NR1H2 | GRIN2D 671/4885GRIN3B 333/4885GRIN1 341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.